Optimizing Your Health: How Long Can I Take Wegovy® for Sustainable Weight Management?

Last reviewed: June 29, 2026

Last updated: June 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no maximum duration in the Wegovy label. The Wegovy prescribing information indicates the medication, in combination with a reduced calorie diet and increased physical activity, "to reduce excess body weight and maintain weight reduction long term" — and that phrase, "long term," is doing real work. It signals that the drug was studied and approved as an ongoing treatment for a chronic condition, not as a course of therapy you finish. How long you take it is a clinical decision made by the prescriber who is monitoring your response, your tolerability, and your other conditions. What the evidence can tell you is what happened to people who kept taking semaglutide for two years and beyond, and what happened to people who stopped.

What the Label Says — and What It Deliberately Does Not Say

Wegovy's indications now cover several distinct populations. The injection is labeled to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and in pediatric patients aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition; and, under accelerated approval, for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.

None of those indications carries a stop date, a maximum number of weeks, or a mandatory treatment holiday. That absence is not an oversight. Labels specify duration when the evidence supports a defined course — an antibiotic, a hepatitis regimen. Chronic-disease treatments are labeled open-endedly because the underlying condition does not resolve when the prescription runs out.

The Two-Year Data

The longest dedicated weight-management trial of semaglutide 2.4 mg is STEP 5, a 104-week randomized, double-blind, placebo-controlled study in 304 adults with obesity, or overweight with a weight-related condition, and without diabetes. Mean body weight change at week 104 was −15.2% with semaglutide versus −2.6% with placebo, a treatment difference of −12.6 percentage points, and 77.1% of the semaglutide group reached at least 5% weight loss versus 34.4% on placebo.

One detail from STEP 5 answers a question people ask more often than they realize: weight, waist circumference, blood pressure and HbA1c appeared to plateau around week 60 and were then sustained through week 104. A plateau is not the drug wearing off. It is the point at which the new weight is being held rather than further reduced — which is precisely what "maintain weight reduction long term" describes.

Beyond Two Years: What the Cardiovascular Data Adds

The longest controlled exposure to semaglutide 2.4 mg comes from a trial that was not primarily about weight at all. SELECT enrolled 17,604 adults aged 45 and older with preexisting cardiovascular disease and a body mass index of 27 or greater, without diabetes, randomized to once-weekly semaglutide 2.4 mg or placebo. Mean duration of exposure to trial product was 34.2 months and mean follow-up was 39.8 months.

Over that period a primary cardiovascular endpoint event occurred in 6.5% of the semaglutide group versus 8.0% on placebo (hazard ratio 0.80). Adverse events leading to permanent discontinuation occurred in 16.6% of the semaglutide group versus 8.2% on placebo. Both numbers matter to a duration question: the benefit accrued over years of continuous treatment, and roughly one in six participants stopped for tolerability reasons over that same span.

What Happened When People Stopped

Two trials were designed specifically to answer this. In the STEP 4 randomized withdrawal trial, 803 adults who had completed a 20-week run-in on semaglutide were randomized either to continue or to switch to placebo for 48 more weeks. From week 20 to week 68, the continued-semaglutide group lost a further 7.9% of body weight; the group switched to placebo gained 6.9% — a difference of 14.8 percentage points.

The STEP 1 trial extension followed 327 participants for a year after all treatment, including the lifestyle intervention, was withdrawn at week 68. Mean weight loss at week 68 had been 17.3% with semaglutide. By week 120, participants had regained 11.6 percentage points of that loss, leaving a net 5.6% below baseline, and most cardiometabolic improvements had reverted toward baseline. The authors' conclusion was blunt: the findings "confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health."

Duration Is Not the Same Question as Dose or Formulation

Wegovy is no longer a single presentation, which changes what "how long" can mean in practice. The injection is supplied in single-dose pens ranging from 0.25 mg/0.5 mL to 7.2 mg/0.75 mL, the last of these being Wegovy HD, and in a single-patient-use FlexTouch pen. Wegovy tablets are supplied in 1.5 mg, 4 mg, 9 mg and 25 mg strengths, with a labeled maintenance dosage of 25 mg once daily and a narrower set of indications than the injection.

A person may stay on treatment for years while the specific product or strength changes more than once. That is a labeling and prescribing matter, and the decision sits with the clinician who has your full record. Nothing about the schedule — starting, adjusting, pausing, or stopping — should be taken from an article, including this one.

How Long-Term Treatment Actually Gets Reassessed

In practice, an ongoing prescription is not a set-and-forget arrangement. Prescribers re-evaluate whether the medication is still producing benefit, whether side effects remain acceptable, whether other conditions or medications have changed, and whether the treatment still fits the person's goals. Coverage, cost and supply are separate practical constraints that also shape how long people actually stay on therapy, independent of clinical need.

What the trial evidence argues against is the framing many people arrive with — that there is a finish line, and the job is to reach it and then step off. Both STEP 4 and the STEP 1 extension tested that framing directly, and in both cases weight and cardiometabolic markers moved back toward where they started.

Where Compounded Semaglutide Fits

Compounded semaglutide is not an FDA-approved finished product, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. It is not a generic version of Wegovy — there is no approved generic semaglutide.

That distinction matters for a duration question because the long-term evidence discussed above was generated with the approved products at studied doses. Anyone weighing months or years of treatment should be having that conversation with a licensed prescriber who knows what they are actually taking.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

How long can I take Wegovy?

The Wegovy prescribing information sets no maximum duration. It indicates the medication to reduce excess body weight and maintain weight reduction long term, language that describes ongoing treatment of a chronic condition rather than a fixed course. The actual length of your treatment is a clinical decision made by your prescriber based on your response, tolerability, other conditions and goals, and it is reassessed over time rather than set at the start.

What does the evidence show for taking semaglutide longer than a year?

STEP 5 followed 304 adults for 104 weeks and reported mean weight change of −15.2% with semaglutide 2.4 mg versus −2.6% with placebo, with reductions appearing to plateau around week 60 and holding through two years. The SELECT cardiovascular outcomes trial exposed 8,803 people to semaglutide 2.4 mg for a mean of 34.2 months, with a mean follow-up of 39.8 months.

What happens if I stop taking Wegovy?

Two trials tested this directly. In STEP 4, participants who switched to placebo after a 20-week run-in gained 6.9% of body weight over the next 48 weeks while those who continued lost a further 7.9%. In the STEP 1 extension, participants regained 11.6 of the 17.3 percentage points they had lost within one year of stopping, and most cardiometabolic improvements reverted toward baseline.

Does that mean I have to take it forever?

No article can answer that for an individual. What the published trials show is that the weight reduction and cardiometabolic benefits observed on treatment largely reverted when treatment was withdrawn, which is why the STEP 1 investigators concluded that ongoing treatment appears necessary to maintain those improvements. Whether to continue, adjust or stop is a decision for you and your prescriber, informed by your results and tolerability.

Is compounded semaglutide the same as Wegovy?

No. Compounded semaglutide is not an FDA-approved finished product, and the FDA does not review compounded drugs for safety, effectiveness or quality before marketing. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. Wegovy is the FDA-approved semaglutide product for chronic weight management, and there is no approved generic version of it.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.